CoChat

Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes

Tseng, Chin‐Hsiao · 2018 · Liver International
Cited by 132

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Background: Whether metformin may reduce hepatocellular carcinoma (HCC) risk requires confirmation. Methods: Type 2 diabetes patients newly diagnosed during 1999‐2005 and with 2 or more prescriptions of antidiabetic drugs were enrolled from the Taiwan’s National Health Insurance database. A total of 173 917 ever‐users and 21 900 never‐users of metformin were identified (unmatched cohort). A 1:1 matched‐pair cohort of 21 900 ever‐users and 21 900 never‐users based on a propensity score (PS) was created. Hazard ratios were estimated by Cox regression incorporated with the inverse probability of treatment weighting using the PS. In addition, interactions with aspirin and statin were evaluated. Results: In the unmatched cohort, 619 never‐users and 2642 ever‐users developed HCC, with a respective incidence of 668.0 and 330.7 per 100 000 person‐years and an overall hazard ratio of 0.49 (95% confidence interval: 0.45‐0.54). The hazard ratios for the first (<25.7 months), second (25.7‐56.9 months) and third (>56.9 months) tertile of cumulative duration of metformin therapy were 0.89 (0.81‐0.98), 0.50 (0.46‐0.56) and 0.23 (0.21‐0.26) respectively. Analyses of the matched cohort showed an overall hazard ratio of 0.76 (0.67‐0.85), and the hazard ratios for the respective tertiles were 1.39 (1.19‐1.62), 0.77 (0.65‐0.91) and 0.37 (0.30‐0.45). Aspirin and statin were observed to have a significant interaction with metformin. Conclusions: Metformin was associated with a reduced risk of HCC in a dose‐response pattern. Users of both metformin and aspirin or metformin and statin had the lowest risk.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/liv.13872

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 132

Metadata

Authors
Tseng, C.
Venue
Liver International
Publisher
Wiley
Published
2018-06-29
Volume
38
Issue
11
Pages
2018-2027
ISSN
  • 0106-9543 (ISSN-L)
  • 1478-3223
  • 1478-3231
OpenAlex
W2809909380
Cited by
132
References
3
FWCI
4.63
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes. https://app.cochat.ai/papers/10.1111/liv.13872
The paper
Tseng, C. (2018). Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes. Liver International. https://doi.org/10.1111/liv.13872

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.